Israel - English - Ministry of Health

dexcel ltd, israel - rivaroxaban - film coated tablets - rivaroxaban 15 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric population: treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing from 30 kg to 50 kg after at least 5 days of initial parenteral anticoagulation treatment

Israel - English - Ministry of Health

dexcel ltd, israel - rivaroxaban - film coated tablets - rivaroxaban 2.5 mg - rivaroxaban - rivaroxaban dexcel 2.5 mg, co-administered with acetylsalicylic acid (asa) alone or with asa plus clopidogrel, is indicated for the prevention of atherothrombotic events in adult patients after an acute coronary syndrome (acs) with elevated cardiac biomarkers.rivaroxaban dexcel 2.5 mg, co-administered with acetylsalicylic acid (asa), is indicated for the prevention of atherothrombotic events in adult patients with coronary artery disease (cad) or symptomatic peripheral artery disease (pad) at high risk of ischaemic events.

Israel - English - Ministry of Health

dexcel ltd, israel - rivaroxaban - film coated tablets - rivaroxaban 20 mg - rivaroxaban - prevention of stroke and systemic embolism in adult patients with non-valvular atrial fibrillation with one or more risk factors, such as congestive heart failure, hypertension, age≥75 years, diabetes mellitus, prior stroke or transient ischaemic attack.treatment of deep vein thrombosis (dvt) and pulmonary embolism (pe), and prevention of recurrent dvt and pe in adults.paediatric population: treatment of venous thromboembolism (vte) and prevention of vte recurrence in children and adolescents aged less than 18 years and weighing more than 50 kg after at least 5 days of initial parenteral anticoagulation treatment.

Philippines - English - FDA (Food And Drug Administration)

a. menarini philippines, inc - mesalazine - rectal suppository - 250mg

Philippines - English - FDA (Food And Drug Administration)

a.menarini philippines, inc. - mesalazine - rectal suspension for enema - 4g/60ml

United States - English - NLM (National Library of Medicine)

nextmune ab - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - clxderm™ 4% chlohexidine digluconate antiseptic shampoo for dogs and cats for use on dogs and cats only to maintain healthy skin and hair and to enhance hygiene. aids in the management of skin infections associated with micro-organisms that are sensitive to chlorhexidine.

United States - English - NLM (National Library of Medicine)

nextmune ab - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - chlorhexidine digluconate topical antiseptic and moisturizer for dogs and cats. for topical use on dogs and cats only to aid in the management of skin infections associated with micro-organisms that are sensitive to chlorhexidine.

United States - English - NLM (National Library of Medicine)

nextmune ab - chlorhexidine gluconate (unii: mor84mud8e) (chlorhexidine - unii:r4ko0dy52l) - ear cleaning chlorhexidine digluconate solution to remove excess ear wax in dogs and cats indications: for cleaning and removal of excess cerumen (ear wax) in dogs and cats.